GlobeNewswire Press

  1. Mustang Bio Announces City Of Hope Opens First-Of-Its-Kind Multiple Myeloma CAR T Cell Therapy Trial Targeting CS1 Protein 5/8/2019

    Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced that City of Hope, a world-renowned independent cancer research and treatment center, has begun enrolling patients with relapsed or treatment-resistant multiple myeloma in an innovative CS1 chimeric antigen receptor (CAR) T cell therapy (MB-104) trial.

  2. GW Pharmaceuticals Reports Positive Phase 3 Pivotal Trial Results For EPIDIOLEX® Oral Solution In Patients With Seizures Associated With Tuberous Sclerosis Complex 5/6/2019

    GW Pharmaceuticals plc and its U.S. subsidiary Greenwich Biosciences Inc. (NASDAQ: GWPH, GW, the Company or the Group), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, today announced positive top-line results of a randomized, double-blind, placebo-controlled Phase 3 clinical trial of EPIDIOLEX® (cannabidiol or CBD) CV in the treatment of seizures associated with Tuberous Sclerosis Complex (TSC), a rare and severe form of childhood-onset epilepsy.

  3. Dynavax Announces First Patient Enrolled In Study Of HEPLISAV-B® [Hepatitis B Vaccine, Recombinant (Adjuvanted)] In Adults With End-Stage Renal Disease 5/2/2019

    Dynavax Technologies Corporation (NASDAQ: DVAX), a fully-integrated biopharmaceutical company focused on discovering, developing and commercializing novel vaccines and immuno-oncology therapeutics, today announced the enrollment of the first patient in the company’s open-label, single-arm study of HEPLISAV-B in adults with end-stage renal disease who are initiating or undergoing hemodialysis.

  4. Samumed Launches Phase 3 Lorecivivint (SM04690) Clinical Program In Knee Osteoarthritis 5/2/2019

    Samumed, LLC, announced today that it has finalized the design of its phase 3 clinical program of lorecivivint (SM04690) for the treatment of knee osteoarthritis (OA), which will consist of pivotal trials studying the effects of lorecivivint on patient-reported outcomes and disease progression.

  5. XBiotech Announces Enrollment Completion, Positive Findings For Bermekimab In Pancreatic Cancer Study 5/2/2019

    XBiotech Inc. (NASDAQ: XBIT) announced today enrollment of the final patient into its Phase I study1 evaluating bermekimab in patients with advanced pancreatic adenocarcinoma and cachexia.

  6. Checkpoint Therapeutics Announces Positive Interim Clinical Results Of Anti-PD-L1 Antibody Cosibelimab 5/1/2019

    Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immuno-oncology biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for patients with solid tumor cancers, today announced positive interim results from its ongoing multicenter Phase 1 clinical trial of cosibelimab (formerly referred to as CK-301).

  7. HEALIOS K.K. Announces Enrollment Of First Patient In Japan In The ONE-BRIDGE Study Of MultiStem® Treatment For Acute Respiratory Distress Syndrome 4/23/2019

    Athersys, Inc. (Nasdaq: ATHX) announced today that its partner, HEALIOS K.K. (“Healios”), has enrolled the first patient in its ONE-BRIDGE study in Japan, evaluating MultiStem® cell therapy treatment of patients who suffer from acute respiratory distress syndrome (“ARDS”).

  8. Sol-Gel Technologies Announces 50% Enrollment In Pivotal Phase III TWIN Program For The Treatment Of Acne Vulgaris 4/15/2019

    Sol-Gel Technologies Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, announced today that it has completed enrollment of half of the patients in its pivotal Phase III clinical trials of TWIN in subjects with acne vulgaris.

  9. Fibrocell Announces Collaboration With Castle Creek Pharmaceuticals To Develop And Commercialize FCX-007 Gene Therapy 4/15/2019

    Fibrocell Science, Inc. (Nasdaq: FCSC), a cell and gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, today announced the completion of a collaboration agreement with Castle Creek Pharmaceuticals to develop and commercialize Fibrocell’s lead gene therapy candidate, FCX-007, for the treatment of recessive dystrophic epidermolysis bullosa (RDEB), a rare, life-threatening genetic disorder diagnosed at infancy with no cure or treatment approved by the U.S. Food and Drug Administration (FDA).

  10. Sanofi And Alnylam Conclude Research And Option Phase Of 2014 Rare Disease Alliance 4/8/2019

    Sanofi and Alnylam have agreed to conclude the research and option phase of the companies’ 2014 RNAi therapeutics alliance in rare genetic diseases. The material collaboration terms for patisiran, vutrisiran (ALN-TTRsc02) and fitusiran, as previously announced, will continue unchanged.